Showing 5121-5130 of 8624 results for "".
- New Guidelines Offer SRT Treatment Recommendations for Skin Cancers, Keloidshttps://practicaldermatology.com/news/new-guidelines-offer-srt-treatment-recommendations-for-skin-cancers-keloids/2459897/Superficial Radiation Therapy (SRT) should be first-line therapy for appropriate non-melanoma skin cancers in appropriate patients, according to new consensus guidelines<
- Two New Psoriasis Guidelines Address Comorbidities, Biologic Treatmenthttps://practicaldermatology.com/news/two-new-psoriasis-guidelines-address-comorbidities-biologic-treatment/2459901/The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines outlining best practices for treating psoriasis with a focus on comorbidities and biologic treatment. Develo
- Study Shows 97% Cure Rate for Superficial Radiation Therapy for BCC and SCChttps://practicaldermatology.com/news/study-shows-97-cure-rate-for-superficial-radiation-therapy-for-bcc-and-scc/2459900/A new retrospective study shows a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) on their lower extremities with SRT-100TM Superficial Radiation Therapy from Sensus Hea
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- Stelatopia Emollient Face Cream Now Available from Mustelahttps://practicaldermatology.com/news/stelatopia-emollient-face-cream-now-available-from-mustela/2459902/Mustela Stelatopia Emollient Face Cream is now available, specifically designed for extremely dry to eczema-prone skin and gentle enough to use on newborns. Formulated with Avocado Perseose®, which is intended to restore and protect the skin barrier by boosting ceramides a
- Combination Surgical Excision/Laser Treatment Improves Outcomes, Patient Satisfaction for CMNhttps://practicaldermatology.com/news/combination-surgical-excisionlaser-treatment-improves-outcomes-patient-satisfaction-for-cmn/2459908/Combining lasers with surgical excision produces cosmetically superior results compared to laser-only treatments for small to medium congenital melanocytic nevi (CMN), according to a new review. The
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topa
- Study Finds Lack of Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizationshttps://practicaldermatology.com/news/study-finds-lack-of-disclosure-of-potential-conflicts-of-interest-in-dermatology-patient-advocacy-organizations/2459912/A recent study published in JAMA Dermatology was conducted to examine potential financial conflicts of interest and characterize disclosure practices among dermatology patient advocacy organizations. For this cross-sectional study of the largest dermatology patient ad
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp